Agios, Audentes price follow-ons

Cancer company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and gene therapy and rare diseases play Audentes Therapeutics Inc. (NASDAQ:BOLD) raised a total of more than $325 million in follow-ons.

Agios raised $250 million through the sale of 5.1 million shares at $49.50 in a follow-on underwritten by JPMorgan, Goldman Sachs and Cowen. The price is an 11% discount to Agios' closing price of $55.51 on Monday, when it proposed to sell up to 4.5 million shares. Agios lost 9% on Tuesday, and then priced the offering after market hours. Its shares slipped $1.62 to $48.74 on Wednesday...